Business · Companies · 3 hrs ago
Samsung Biologics signs $324.8 million drug manufacturing contract
Samsung Biologics signed a new contract to manufacture biologic medicines for a global pharmaceutical company.
The deal is worth $324.8 million, or 434.3 billion won.
The company did not identify the customer or the medicines, citing confidentiality terms.
The contract is for contract manufacturing, meaning Samsung Biologics will make medicines for another company.
The deal brings cumulative orders above 30 trillion won, a milestone for the company’s business.
The agreement runs through December 31, 2031.
Samsung Biologics announced a new contract to manufacture biologic drugs for a global pharmaceutical company.
The contract is valued at 434.3 billion won, or $324.8 million.
The contract runs through December 31, 2031.
The company and product names were not disclosed because of confidentiality provisions.
The announcement said Samsung Biologics’ cumulative orders had exceeded 30 trillion won.
- Who
- Samsung Biologics and an unnamed global pharmaceutical company.
- What
- A contract for Samsung Biologics to manufacture biologic drugs, valued at $324.8 million.
- When
- Announced on November 3, 2026; the contract runs through December 31, 2031.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Contract value
- 434.3 billion won ($324.8 million)
- Contract end date
- December 31, 2031
- Customer and product
- Not disclosed under confidentiality provisions
- Cumulative orders
- More than 30 trillion won